射频消融治疗甲状腺乳头状癌的研究进展

doi:10.13481/j.1671-587x.20190346

[1] 潘明, 陈闯, 牛志昊,等. 射频消融治疗甲状腺乳头状癌的临床进展[J]. 中国地方病防治杂志, 2015(3):182-183.
[2] HAUGEN B R. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:What is new and what has changed?[J].Cancer,2017,123(3):372-381.
[3] CHANG H, KIM SM, CHUN KW, et al.Clinicopathologic features of solid variant papillary thyroid cancer[J]. ANZ J Surg,2014,84(5):380-382.
[4] KIM J H, YOO W S, PARK Y J, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm[J]. Radiology, 2015,276(3):909-918.
[5] GARBEROGLIO R, ALIBERTI C, APPETECCHIA M, et al. Radiofrequency ablation for thyroid nodules:which indications? The first Italian opinion statement[J]. J Ultrasound, 2015, 18(4):423-430.
[6] 周茂胜, 常欣. 射频消融原理及应用[J]. 当代医学, 2009, 15(21):18-19.
[7] SHIN J E, BAEK J H, LEE J H. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers:Current status and challenges[J]. Current Opinion Oncol, 2012, 25(1):14-19.
[8] FRANZ A M, SEITEL A, BOPP N, et al. First clinical use of the EchoTrack guidance approach for radiofrequency ablation of thyroid gland nodules[J]. Int J Computer Assisted Radiol Surg, 2017, 12(6):931-940.
[9] 刘池拽, 邓建伟, 师天雄. RFA技术在甲状腺疾病中的临床进展[J]. 中华普通外科学文献:电子版, 2015(3):54-57.
[10] XIAOYIN T, DAN C, JIACHANG C, et al. Evaluation of the safety and efficacy of radiofrequency ablation for treating benign thyroid nodules[J]. J Cancer, 2017, 8(5):754-760.
[11] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int Hyperthermia, 2017, 33(2):8.
[12] GUAN Y, LUO Y, ZHANG Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2017,143(8):1555-1562.
[13] KIM C, LEE J H, CHOI Y J, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers[J]. Eur Radiol, 2017, 27(8):3128-3137.
[14] 李建如, 罗渝昆, 李岩密,等. 超声引导下RFA治疗甲状腺微小乳头状癌的疗效分析[J]. 解放军医学院学报, 2016, 37(8):823-826.
[15] 刘晓岭, 黄靖, 孙德胜,等. 超声引导下RFA治疗甲状腺微小乳头状癌的临床体会[J]. 黑龙江医学, 2015(1):69-70.
[16] LONG B, LI L, YAO L, et al. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma[J]. J Cancer Res Therap, 2015, 11(Suppl 8):C244.
[17] MONCHIK J M, DONATINI G, IANNUCCILLI J, et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma[J]. Ann Surg, 2006, 244(2):296-304.
[18] XU D, CHEN L, QIAN C, et al. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma[J]. J Cancer Res Therapeut, 2014, 10(7):144.
[19] 张丹琦,赵滨滨,张素冰. 针刺复合舒芬太尼麻醉在微创甲状腺RFA术中的应用[A]. 中国中西医结合麻醉学会[CSIA]年会暨第二届全国中西医结合麻醉学术研讨会、江苏省中西医结合学会麻醉专业委员会成立大会论文汇编[C]. 扬州:2015.
[20] ITO Y, MIYAUCHI A, KIHARA M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 24(1):27-34.
[21] JEONG S Y, BAEK J H, CHOI Y J, et al.Radiofrequency ablation of primary thyroid carcinoma:efficacy according to the types of thyroid carcinoma[J]. Int J Hyperthermia, 2018,34(5):611-616.
[22] 董文武, 张浩, 张平,等. 甲状腺乳头状癌射频消融治疗后再手术5例临床分析[J]. 中国实用外科杂志, 2015, 35(6):653-655.
[23] YANG L, TANG H, LEE A M, et al. Risk of malignancy in symptomatic nodular goiter treated with radiofrequency ablation[J]. AJNR Am Neuroradiol, 2015, 37(1):E7.
[24] 田文, 王宇, 郗洪庆,等. 甲状腺疾病RFA治疗现状与争议[J]. 中国实用外科杂志, 2018,38(1):75-78.
[25] LIM H K, BAEK J H, LEE J H, et al. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer[J]. Eur Radiol, 2015, 25(1):163-170.
[26] ZHAO Q, TIAN G, KONG D. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers[J]. J Endocrinol Invest, 2016, 39(8):909-916.
[27] MAZZEO S, CERVELLI R, ELISEI R, et al. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation:a prospective study[J]. J Endocrinol Invest,2018,41(12):1389-1399.
[28] 广旸, 罗渝昆, 张艳,等. 超声引导下RFA治疗PTC颈部转移淋巴结的疗效评价[J]. 中国医学科学院学报, 2018(1),40(1):67-71.
[29] BAEK J H, NA D G, PARK H S. RE:Management of low-risk papillary thyroid microcarcinoma[J]. Korean J Radiol, 2017, 18(2):408-409.
[30] CAZZATO R L, BONICHON F, BUY X, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer[J]. Eur J Surg Oncol,2015,41(9):1247-1255.
[31] KIM M, KIM W G, PARK S, et al. Growth kinetics of macronodular lung metastases and survival in differentiated thyroid carcinoma[J]. Thyroid, 2017,27(7):915-922.
[32] MASSICOTTE M H, BRASSARD M, CLAUDE-DESROCHES M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas:a retrospective study of the TUTHYREF network[J]. Eur J Endocrinol, 2014, 170(4):575-582.
[33] 隋洋, 吴凤林, 孙医学. 超声引导下RFA甲状腺结节的并发症与预防方法探讨[J]. 医学影像学杂志, 2014, 24(1):32-35.
[34] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int J Hyperthermia, 2017,33(2):212-219.
[35] 娄雪峰, 吴凤林, 纪莉,等. RFA高风险甲状腺结节避免喉返神经损伤的方法探讨[J]. 中国超声医学杂志, 2014, 30(7):577-580.
[36] BERNARDI S, LANZILOTTI V, PAPA G, et al.Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule[J]. Thyroid, 2016,26(1):183-184.
[37] 马建新, 杜大勇, 李运田. 甲状腺功能减退患者RFA术后出现意识模糊一例[J]. 中国心脏起搏与心电生理杂志, 2009, 23(3):268-268.
[38] ODDO S, SPINA B, VELLONE V G, et al. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation[J]. J Endocrinol Invest, 2017,40(1):101-102.
[39] LEE C U, KIM S J, SUNG J Y, et al. Needle track tumor seeding after radiofrequency ablation of a thyroid tumor[J]. Japan J Radiol, 2014, 32(11):661-663.

Research progress in radiofrequency ablation in treatment of papillary thyroid carcinoma

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Yixuan XU,Hui WANG. Comparison of clinical efficacy between microwave ablation and surgical treatment for Hashimoto’s thyroiditis complicated with T1aN0M0 papillary thyroid carcinoma [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1646-1654.
[2]	Qian AO,Jingting LI,Nan LIANG,Hui SUN. Recurrent follicular variant of papillary thyroid carcinoma with DICER1 mutation in adolescent：A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1702-1708.
[3]	Pengqing WU,Lingpeng ZENG,Zhaoxia LUO,Yangyang LEI,Ruiqin GOU,Qing ZHANG. Thymus physiological uptake in patient with differentiated thyroid carcinoma after postoperative iodine-131 treatment: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1358-1362.
[4]	Lingyu WANG,Weizhang SHEN,Lei TAN,Jinliang LI. Diagnosis of immune thrombotic thrombocytopenic purpura: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1734-1740.
[5]	Shimeng LI,Xin QI,Sitong LIN,Xiangwen SAN,Ling JIN,Sitong ZHANG. Reactive plasmacytosis caused by methimazole in patients with Graves’ disease： One case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1414-1419.
[6]	Yuxiao SHI,Meilan LIU,Meilin ZHU,Feng WEI. Effects of 5-Aza-CdR on autophagy and apoptosis of papillary thyroid cancer cells in subcutaneous xenograft tumor tissue of nude mice and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1330-1338.
[7]	Peng QI,Xianying MENG,Meihua PIAO,Qiang ZHANG. Network Meta-analysis on risk factors of recurrence of papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1504-1512.
[8]	. Research progress in changes of hormone levels of patients with differentiated thyroid carcinoma during pregnancy and their effects on occurrence and development of disease [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 811-815.
[9]	Zhiyuan XIAO,Bing SONG,Xinyu MA,Lianhui JIN,Tong ZHENG,Fang CHAI. Bioinformatics analysis on expression of apoptosis related gene CD44 in thyroid carcinoma tissue and its relationship with tumor invasion and immune cell infiltration [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 473-481.
[10]	Wanyi GU,Cheng ZHI,Chunxia LIU. Intrathyroid thymic carcinoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1580-1585.
[11]	. Research progress in preoperative evaluation and prognostic related factors of low-risk papillary thyroid microcarcinoma [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1650-1656.
[12]	Wei JI,Jian DONG,Hong CHANG,Xuemei DU,Hong PENG,Hong XIE,Aimin ZHAO,Wei YAN,Juan BAI,Zhenxing PENG,Jinshu YIN. Influence of chinicopathological characteristics and BRAF V600E gene mutation in cervical lymph node metastasis in patients with papillary thyroid cancer [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 995-1002.
[13]	Yaoyu FENG, Chenglei ZHANG, Lijuan HOU, Yifu WANG, Xiuling WU, Yunhai MA. Effect of miR-222-3p knockdown targeting PTEN on ¹³¹I radiotherapy resistance of thyroid cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 677-686.
[14]	. [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 802-810.
[15]	Chunying ZHANG,Guangwei YIN,Mingda YOU,Hong CHEN,Yaojie HU,Yanbing LI,Chunyou CHEN. Inhibitory effects of siRNA targeting silencing TAK1 gene on proliferation and migration of thyroid cancer cells and p38 MAPK signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 110-117.